Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. More Details
Outstanding track record and undervalued.
Share Price & News
How has Meridian Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VIVO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VIVO's weekly volatility (9%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: VIVO underperformed the US Medical Equipment industry which returned 34.9% over the past year.
Return vs Market: VIVO underperformed the US Market which returned 52.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Meridian Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StShould Weakness in Meridian Bioscience, Inc.'s (NASDAQ:VIVO) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
1 month ago | Simply Wall StMeridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
1 month ago | Simply Wall StHave Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Is Meridian Bioscience undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VIVO ($19.17) is trading below our estimate of fair value ($64.24)
Significantly Below Fair Value: VIVO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VIVO is good value based on its PE Ratio (11.7x) compared to the US Medical Equipment industry average (57.4x).
PE vs Market: VIVO is good value based on its PE Ratio (11.7x) compared to the US market (20.4x).
Price to Earnings Growth Ratio
PEG Ratio: VIVO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: VIVO is good value based on its PB Ratio (3x) compared to the US Medical Equipment industry average (4.9x).
How is Meridian Bioscience forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIVO's earnings are forecast to decline over the next 3 years (-8.3% per year).
Earnings vs Market: VIVO's earnings are forecast to decline over the next 3 years (-8.3% per year).
High Growth Earnings: VIVO's earnings are forecast to decline over the next 3 years.
Revenue vs Market: VIVO's revenue is expected to decline over the next 3 years (-3.8% per year).
High Growth Revenue: VIVO's revenue is forecast to decline over the next 3 years (-3.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VIVO's Return on Equity is forecast to be high in 3 years time
How has Meridian Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIVO has high quality earnings.
Growing Profit Margin: VIVO's current net profit margins (23.4%) are higher than last year (9.7%).
Past Earnings Growth Analysis
Earnings Trend: VIVO's earnings have grown by 6.6% per year over the past 5 years.
Accelerating Growth: VIVO's earnings growth over the past year (266.7%) exceeds its 5-year average (6.6% per year).
Earnings vs Industry: VIVO earnings growth over the past year (266.7%) exceeded the Medical Equipment industry 10.8%.
Return on Equity
High ROE: VIVO's Return on Equity (25.2%) is considered high.
How is Meridian Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: VIVO's short term assets ($177.6M) exceed its short term liabilities ($53.8M).
Long Term Liabilities: VIVO's short term assets ($177.6M) exceed its long term liabilities ($91.2M).
Debt to Equity History and Analysis
Debt Level: VIVO's debt to equity ratio (21.3%) is considered satisfactory.
Reducing Debt: VIVO's debt to equity ratio has increased from 0.8% to 21.3% over the past 5 years.
Debt Coverage: VIVO's debt is well covered by operating cash flow (113.9%).
Interest Coverage: VIVO's interest payments on its debt are well covered by EBIT (38.8x coverage).
What is Meridian Bioscience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VIVO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VIVO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VIVO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VIVO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: VIVO is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VIVO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jack Kenny (51 yo)
Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017. Mr. Kenny serves as President of Meridian Bioscience, Inc. and served as its ...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD3.33M) is above average for companies of similar size in the US market ($USD2.34M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.
Experienced Management: VIVO's management team is considered experienced (2.3 years average tenure).
Experienced Board: VIVO's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VIVO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Meridian Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Meridian Bioscience, Inc.
- Ticker: VIVO
- Exchange: NasdaqGS
- Founded: 1976
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$830.110m
- Shares outstanding: 43.15m
- Website: https://www.meridianbioscience.com
Number of Employees
- Meridian Bioscience, Inc.
- 3471 River Hills Drive
- United States
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/06 22:59|
|End of Day Share Price||2021/05/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.